On October 30, Tempus AI fell 5.19% in After-Hours Trading, trading at $73.81 per share, with turnover of $18.43 million.
The move coincided with disclosure that executive Eric Lefkofsky planned to sell 250,000 Class A common shares, with an indicated value of about $16.79 million, a development that appeared to weigh on near-term market sentiment.
Recent company-specific news had been constructive, including expectations for quarterly revenue growth of 24.53%, projected diagnostics revenue of $289 million representing 75.65% of total revenue, narrowing losses, and EU IVDR Class C certification for its xR solid tumor RNA sequencing assay. Even so, the latest after-hours reaction was more closely tied to the insider sale filing than to those operational positives.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments